Tags

Type your tag names separated by a space and hit enter

Human papillomavirus infection and cervical cancer prevention in Japan and Korea.
Vaccine. 2008 Aug 19; 26 Suppl 12:M30-42.V

Abstract

Cervical cancer is a common cancer among women in Japan and Korea. Implementation of national cervical cancer screening programs has led to a reduction in the incidence of cervical cancer in both countries. However, over the past decade, there has been a recent marked increase in cervical cancer incidence among young women in Japan. Human papillomavirus (HPV) is found in the majority of cervical cancers, and HPV-16 and 18 are the two most common types. The next most frequent HPV types in cervical cancer are 52, 58 and 33 for Japan and 52, 58, and 33 for Korea, varying slightly when compared to the worldwide distribution. Screening coverage for both countries remains a challenge. Current coverage is reported at 24% in Japan, with the lowest coverage in young Japanese women, and 41% in Korea. Cytology remains the predominant screening method. HPV DNA testing is widely used to triage women with abnormal cytology in Korea. HPV vaccines have been licensed in Korea, but not yet in Japan. In both countries cost is a substantial impediment to implementation and no national programs are currently planned or in place. Therefore, increased disease awareness and utilization of screening is the first priority for controlling cervical cancer.

Authors+Show Affiliations

Department of Gynecology, Jichi Medical University, Saitama Medical Center, Omiya, Saitama, Japan. kryo772007@yahoo.co.jpNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18945412

Citation

Konno, Ryo, et al. "Human Papillomavirus Infection and Cervical Cancer Prevention in Japan and Korea." Vaccine, vol. 26 Suppl 12, 2008, pp. M30-42.
Konno R, Shin HR, Kim YT, et al. Human papillomavirus infection and cervical cancer prevention in Japan and Korea. Vaccine. 2008;26 Suppl 12:M30-42.
Konno, R., Shin, H. R., Kim, Y. T., Song, Y. S., Sasagawa, T., Inoue, M., & Park, J. S. (2008). Human papillomavirus infection and cervical cancer prevention in Japan and Korea. Vaccine, 26 Suppl 12, M30-42. https://doi.org/10.1016/j.vaccine.2008.05.006
Konno R, et al. Human Papillomavirus Infection and Cervical Cancer Prevention in Japan and Korea. Vaccine. 2008 Aug 19;26 Suppl 12:M30-42. PubMed PMID: 18945412.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Human papillomavirus infection and cervical cancer prevention in Japan and Korea. AU - Konno,Ryo, AU - Shin,Hai-Rim, AU - Kim,Young-Tak, AU - Song,Yong Sang, AU - Sasagawa,Toshiyuki, AU - Inoue,Masaki, AU - Park,Jong-Sup, PY - 2008/11/1/pubmed PY - 2008/12/19/medline PY - 2008/11/1/entrez SP - M30 EP - 42 JF - Vaccine JO - Vaccine VL - 26 Suppl 12 N2 - Cervical cancer is a common cancer among women in Japan and Korea. Implementation of national cervical cancer screening programs has led to a reduction in the incidence of cervical cancer in both countries. However, over the past decade, there has been a recent marked increase in cervical cancer incidence among young women in Japan. Human papillomavirus (HPV) is found in the majority of cervical cancers, and HPV-16 and 18 are the two most common types. The next most frequent HPV types in cervical cancer are 52, 58 and 33 for Japan and 52, 58, and 33 for Korea, varying slightly when compared to the worldwide distribution. Screening coverage for both countries remains a challenge. Current coverage is reported at 24% in Japan, with the lowest coverage in young Japanese women, and 41% in Korea. Cytology remains the predominant screening method. HPV DNA testing is widely used to triage women with abnormal cytology in Korea. HPV vaccines have been licensed in Korea, but not yet in Japan. In both countries cost is a substantial impediment to implementation and no national programs are currently planned or in place. Therefore, increased disease awareness and utilization of screening is the first priority for controlling cervical cancer. SN - 0264-410X UR - https://www.unboundmedicine.com/medline/citation/18945412/Human_papillomavirus_infection_and_cervical_cancer_prevention_in_Japan_and_Korea_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(08)00578-1 DB - PRIME DP - Unbound Medicine ER -